Meeting
2022 ASCO Genitourinary Cancers Symposium
Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.
Authors
Carmen Alvarez-Dominguez
IDIVAL, Santander, Spain
Carmen Alvarez-Dominguez , Ainara Azueta , Nerea Muñoz Unceta , Jose Luis Gutierrez-Baños , Hector Teran , Javier Ocejo-Viñals , Elena Gonzalez-Lopez , Belen Caramelo , Sara Marcos-Gonzalez , David Salcines-Cuevas , Mario Dominguez , Rebeca Madureira-Rivero , Felix Campos-Juanatey , Marta Sotelo , Andrea Zeoli , Laura Revuelta , Ignacio Duran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 538)
DOI
10.1200/JCO.2022.40.6_suppl.538
Abstract #
538
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
First Author: Michael Wang
Poster
2016 ASCO Annual Meeting
Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.
First Author: Matthew Reilley
First Author: Thai Huu Ho
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells.
First Author: Frances Jenkins Bennett